• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

    11/13/24 11:14:34 AM ET
    $BBLG
    Industrial Specialties
    Health Care
    Get the next $BBLG alert in real time by email
    SC 13G/A 1 ea022071802-13ga1intra_bone.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    Bone Biologics Corporation

     

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

     

    (Title of Class of Securities)

     

    098070501

    (CUSIP Number)

     

    September 30, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a. ☐ Rule 13d-1(b)
    b. ☒Rule 13d-1(c)
    c. ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    Page 1 of 6

     

     

    CUSIP No.     098070501

     

     

    1. Names of Reporting Persons.
       
      Mitchell P. Kopin
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
    3. SEC Use Only
       
    4. Citizenship or Place of Organization          United States of America
       

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting
    Person With:
    5. Sole Voting Power 0
     
    6. Shared Voting Power 110,122
     
    7. Sole Dispositive Power 0
     
    8. Shared Dispositive Power 110,122
     

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person     110,122 (see Item 4)
       
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)   ☐
       
    11. Percent of Class Represented by Amount in Row (9)      4.99% (see Item 4)
       
    12. Type of Reporting Person (See Instructions)
       
      IN; HC

     

    Page 2 of 6

     

     

    CUSIP No.     098070501

     

     

    1. Names of Reporting Persons.
       
      Daniel B. Asher
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
    3. SEC Use Only
       
    4. Citizenship or Place of Organization          United States of America
       

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting
    Person With:
    5. Sole Voting Power 0
     
    6. Shared Voting Power 110,122
     
    7. Sole Dispositive Power 0
     
    8. Shared Dispositive Power 110,122
     

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person     110,122 (see Item 4)
       
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)   ☐
       
    11. Percent of Class Represented by Amount in Row (9)      4.99% (see Item 4)
       
    12. Type of Reporting Person (See Instructions)
       
      IN; HC

     

    Page 3 of 6

     

     

    CUSIP No.     098070501

     

     

    1. Names of Reporting Persons.
       
      Intracoastal Capital LLC
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
    3. SEC Use Only
       
    4. Citizenship or Place of Organization          Delaware
       

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting
    Person With:
    5. Sole Voting Power 0
     
    6. Shared Voting Power 110,122
     
    7. Sole Dispositive Power 0
     
    8. Shared Dispositive Power 110,122
     

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person     110,122 (see Item 4)
       
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)   ☐
       
    11. Percent of Class Represented by Amount in Row (9)      4.99% (see Item 4)
       
    12. Type of Reporting Person (See Instructions)
       
      OO

     

    Page 4 of 6

     

     

    This Amendment No. 1 is being filed jointly by the Reporting Persons and amends the Schedule 13G initially filed by the Reporting Persons with the Securities and Exchange Commission (the “SEC”) on March 14, 2024 (the “Schedule 13G”).

     

    Except as set forth below, all Items of the Schedule 13G remain unchanged. All capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13G.

     

    Item 4.Ownership.

     

    (a) and (b):

     

    As of the close of business on September 30, 2024, each of the Reporting Persons may have been deemed to have beneficial ownership of 110,122 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (“Intracoastal Warrant 1”), and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 4.99% of the Common Stock, based on (1) 2,096,740 shares of Common Stock outstanding as of September 23, 2024, as reported by the Issuer, plus (2) 110,122 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 85,191 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (II) 195,313 shares of Common Stock issuable upon exercise of a second warrant held by Intracoastal (“Intracoastal Warrant 2”) because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (III) 27 shares of Common Stock issuable upon exercise of a third warrant held by Intracoastal (“Intracoastal Warrant 3”) because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock and (IV) 37,110 shares of Common Stock issuable upon exercise of a fourth warrant held by Intracoastal (“Intracoastal Warrant 4”) because Intracoastal Warrant 4 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 4 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 427,763 shares of Common Stock.

     

    (c)Number of shares as to which each Reporting Person has:

     

    (i)Sole power to vote or to direct the vote: 0.

     

    (ii)Shared power to vote or to direct the vote: 110,122.

     

    (iii)Sole power to dispose or to direct the disposition of 0.

     

    (iv)Shared power to dispose or to direct the disposition of 110,122.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ.

     

    Item 10.Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 5 of 6

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 13, 2024

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
       
      /s/ Daniel B. Asher
      Daniel B. Asher
       
      Intracoastal Capital LLC
         
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

    Page 6 of 6

     

    Get the next $BBLG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BBLG

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BBLG
    Leadership Updates

    Live Leadership Updates

    See more
    • Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

      Brings 30+ years of commercial experience in the orthopedic and spine industry Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces the appointment of Phillip T. Meikle to the Company's board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The number of directors of Bone Biologics remains at four. Mr. Meikle most recently was president and chief executive officer of Biosystems of New England, Inc., an orthopedic distribution company that he founded in 1992 and sold to Stryker Corporation in 2019. He

      10/21/24 8:00:00 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors

      Brings 20+ years of experience in finance and business operations at both public and private life sciences companies Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, today announced that effective immediately Robert E. Gagnon has been named to the Company's board of directors. Mr. Gagnon fills the seat left by Erick Lucera, who has resigned effective upon Mr. Gagnon's appointment. The number of directors of Bone Biologics remains at four. Mr. Gagnon is currently chief financial officer of Remix Therapeutics, a clinical stage company focused on small molecule-mediated reprogramming of RN

      1/11/24 8:00:00 AM ET
      $BBLG
      Industrial Specialties
      Health Care

    $BBLG
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Bone Biologics Corp

      DEF 14A - Bone Biologics Corp (0001419554) (Filer)

      4/23/25 8:00:36 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form PRE 14A filed by Bone Biologics Corp

      PRE 14A - Bone Biologics Corp (0001419554) (Filer)

      4/11/25 5:05:39 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form 8-K filed by Bone Biologics Corp

      8-K - Bone Biologics Corp (0001419554) (Filer)

      4/1/25 5:15:18 PM ET
      $BBLG
      Industrial Specialties
      Health Care

    $BBLG
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $BBLG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $BBLG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

      Brings 30+ years of commercial experience in the orthopedic and spine industry Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces the appointment of Phillip T. Meikle to the Company's board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The number of directors of Bone Biologics remains at four. Mr. Meikle most recently was president and chief executive officer of Biosystems of New England, Inc., an orthopedic distribution company that he founded in 1992 and sold to Stryker Corporation in 2019. He

      10/21/24 8:00:00 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

      Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, chief executive officer, will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York City. Bone Biologics' company presentation will be available here beginning on Monday, September 9th at 7:00 a.m. Eastern time. The presentation will be available on the company's website for a period of time here. Management is available throughout the conference for virtual one-on-one meetings. Institutional investors and industry professionals can regis

      9/4/24 8:00:00 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

      Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 781,251 shares of its common stock having an exercise price of $2.43 per share, originally issued in March 2024. The issuance of the shares of common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No. 333-276771). H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for t

      8/2/24 8:00:00 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

      SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

      11/14/24 7:19:34 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

      SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

      11/13/24 11:14:34 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

      SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

      6/28/24 4:15:43 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Frelick Jeff

      4 - Bone Biologics Corp (0001419554) (Issuer)

      1/21/25 6:10:12 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Walsh Deina H

      4 - Bone Biologics Corp (0001419554) (Issuer)

      1/21/25 6:06:14 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Director Meikle Phillip Terry Ii

      4 - Bone Biologics Corp (0001419554) (Issuer)

      10/18/24 8:27:04 PM ET
      $BBLG
      Industrial Specialties
      Health Care